ArticleBMC pregnancy and childbirth2026
Effectiveness of a lifestyle intervention for pregnant women with abnormal glucose metabolism in early pregnancy (EAGM): protocol for a multicentre, open-labelled, two-arm, pragmatic randomised controlled trial.
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06767722 (Effectiveness of a Lifestyle Intervention for Pregnant Women With Abnormal Glucose Metabolism in Early Pregnancy), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effectiveness of a Lifestyle Intervention for Pregnant Women With Abnormal Glucose Metabolism in Early Pregnancy: EAGM Randomized Controlled Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionUniversal screening for hyperglycaemia in women without pregestational diabetes in China has led to a significant rise in the detection of abnormal glucose metabolism in early pregnancy (EAGM), defined as elevated fasting blood glucose (FPG, 5.1–6.9 mmol/L or 92–124 mg/dL) and/or haemoglobin A1c (HbA1c, 5.7%-6.4% or 41–47 mmol/mol) levels in the first trimester (< 14 weeks' gestation). EAGM is correlated with adverse pregnancy outcomes. However, whether early treatment can improve maternal and neonatal outcomes remains unclear.
methodsWe present a protocol (V1.0, date August 15, 2024) for the EAGM trial, which is a multicentre, open-labelled, two-arm, pragmatic randomised controlled trial in China. Eligible pregnancies with EAGM will be recruited from 17 hospitals. Participants (N = 3430) will be randomly allocated in a 1:1 ratio to the intervention group or the control group. The intervention group will begin early lifestyle intervention combined with routine prenatal care from < 15 weeks' gestation, while the control group will receive routine prenatal care alone. All participants will undergo an oral glucose tolerance test at 24–28 weeks' gestation, and whether to continue the intervention will depend on the test result. The primary outcome is a composite neonatal outcome of large-for-gestational-age and preterm birth at < 37 weeks' gestation. DISCUSSION: The EAGM trial is the first large-scale randomised controlled trial in China designed to evaluate the effectiveness of early lifestyle intervention for pregnant women with EAGM, identified by elevated HbA1c and/or FPG before 14 weeks' gestation. The findings are anticipated to provide high-quality evidence to guide future screening strategies and clinical management of early hyperglycaemia in pregnancy.
trial registrationClinicalTrials.gov: NCT06767722. Registered 10 January 2025.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.